Hims & Hers Earnings Reports

Hims & Hers delivered exceptional financial performance in Q1 2025, more than doubling revenue year-over-year and significantly increasing profitability across key metrics, driven by personalized treatments and expansion in weight loss solutions.

Hims & Hers Health, Inc. delivered strong Q4 2024 results with a 95% year-over-year revenue growth to $481.1 million. The company also reported a net income of $26.0 million, significantly higher than the prior year’s $1.2 million. Adjusted EBITDA reached $54.1 million, up from $20.6 million in Q4 2023, and free cash flow rose to $59.5 million from $10.8 million a year ago.

Hims & Hers Health, Inc. reported a strong third quarter in 2024 with revenue of $401.6 million, up 77% year-over-year. The company achieved a net income of $75.6 million and Adjusted EBITDA of $51.1 million. Subscriber base grew to 2.0 million, a 44% increase year-over-year. The company also raised its full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million.

Hims & Hers Health, Inc. reported a 52% year-over-year revenue increase to $315.6 million in Q2 2024. The company achieved a net income of $13.3 million and grew its subscriber base to 1.9 million, up 43% year-over-year. Hims & Hers also raised its full year 2024 revenue guidance to $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to $140 million to $155 million.

Hims & Hers Health, Inc. reported strong first quarter 2024 financial results with revenue of $278.2 million, a 46% increase year-over-year. The company achieved a net income of $11.1 million and subscriber growth to 1.7 million. They also raised full year 2024 guidance to a range of $1.20 billion to $1.23 billion.

Hims & Hers Health, Inc. reported strong Q4 2023 financial results, with a 47% increase in revenue to $246.6 million and a net income of $1.2 million. The company also saw a 48% year-over-year increase in subscribers, reaching 1.5 million. Adjusted EBITDA was $20.6 million for the quarter.

Hims & Hers Health, Inc. reported a 57% year-over-year increase in revenue to $226.7 million for Q3 2023. The company achieved Adjusted EBITDA profitability of $12.3 million and grew its subscriber base to 1.4 million. They raised their full year 2023 revenue guidance to a range of $868 million to $873 million and Adjusted EBITDA guidance to a range of $43 million to $46 million.

Hims & Hers Health, Inc. reported strong second-quarter results with significant revenue growth of 83% year-over-year, reaching $207.9 million. The company also achieved Adjusted EBITDA profitability of $10.6 million and subscriber growth to 1.3 million. The company raised its full-year revenue guidance to $830 million to $850 million and Adjusted EBITDA guidance to $35 million to $40 million.

Hims & Hers Health, Inc. reported an 88% year-over-year increase in revenue to $190.8 million for Q1 2023. The company achieved adjusted EBITDA profitability of $6.1 million and grew its subscriber base to over 1.2 million. They also raised the full year 2023 revenue guidance to a range of $810 million to $830 million and Adjusted EBITDA guidance to a range of $25 million to $30 million.

Hims & Hers Health, Inc. reported a record fourth quarter with a 97% increase in revenue year-over-year, reaching $167.2 million. The company also achieved Adjusted EBITDA profitability of $3.9 million and surpassed one million subscribers. For the full year 2022, revenue increased by 94% to $526.9 million.

Hims & Hers Health, Inc. reported exceptional performance in Q3 2022, with a 95% increase in revenue year-over-year. Net new subscriptions reached an all-time high, and the company raised its full-year 2022 revenue and Adjusted EBITDA guidance. The company expects Adjusted EBITDA profitability beginning in Q4 2022.

Hims & Hers Health, Inc. reported an 87% increase in quarterly revenue, reaching $113.6 million in Q2 2022. The company saw record growth in net new subscriptions for the second straight quarter, ending with 817,000 subscriptions. Due to this momentum, the company raised its full year 2022 revenue guidance to $470 million to $485 million and Adjusted EBITDA guidance to $(27) million to $(20) million.

Hims & Hers Health, Inc. reported strong first-quarter 2022 results, with revenue reaching $101.3 million, up 94% year-over-year. The company also experienced its largest-ever quarterly gain in member subscriptions, increasing by 101,000 to a total of 710,000. The company raises full year 2022 revenue guidance to the range of $410.0 million to $425.0 million and maintains Adjusted EBITDA guidance in the range of $(30.0) million to $(20.0) million

Hims & Hers Health, Inc. reported a strong Q4 2021 with revenue reaching $84.7 million, a 104% increase year-over-year, and ending member subscriptions growing 95% year-over-year to 609,000. The company exceeded its revenue and Adjusted EBITDA guidance for both Q4 2021 and the full year 2021.

Hims & Hers Health, Inc. reported a revenue increase of 79% year-over-year to $74.2 million for Q3 2021. Ending member subscriptions grew 95% year-over-year to 551,000. The company exceeded its Q3 2021 revenue guidance and raised its full year 2021 guidance.

Hims & Hers Health, Inc. reported a 69% year-over-year increase in revenue to $60.7 million for Q2 2021. The company is focused on building a unified consumer platform across multiple medical specialties.

Hims & Hers Health, Inc. reported a strong first quarter in 2021, with revenue increasing by 74% year-over-year to $52.3 million. The company's gross margin improved to 77%, and it ended the quarter with 391,000 subscriptions, up nearly 80% year-over-year. However, the net loss increased to $(51.4) million due to one-time stock-based compensation and transaction bonus expenses related to the merger.